Search results
Read Anthony Fauci's full opening statement to Congress
Newsweek· 21 hours agoDr. Anthony Fauci, the former director of the National Institute of Allergy and Infectious Diseases...
Top US government scientist grilled on COVID
Medical Xpress· 18 hours agoRepublicans accuse the 83-year-old immunologist of helping to set off the worst pandemic in a century by approving funding passed on to Chinese...
Anthony Fauci testifies before House panel on Covid-19 origins
South China Morning Post· 19 hours agoA US intelligence analysis says there is insufficient evidence to prove either way – and a recent...
Small Business - Picayune Item | Picayune Item
The Picayune Item· 7 hours agoGHENT, Belgium, June 04, 2024 (GLOBE NEWSWIRE) -- ExeVir Bio, a biotech company developing robust heavy chain-only antibody therapies for broad protection against infectious diseases, today announced new data demonstrating that its antibodies
Fauci pushes back at fiery hearing
The Hill· 16 hours agoFauci, who ran the National Institute of Allergy and Infectious Diseases for four decades before retiring in 2022, faced heated questions from...
Fauci testifies publicly before House panel on COVID origins, controversies
KIRO 7 Seattle-Tacoma· 22 hours agoWASHINGTON — (AP) — Dr. Anthony Fauci, the top U.S. infectious disease expert until leaving the...
Fauci testifies publicly before House panel on COVID origins, controversies
CW39 NewsFix· 21 hours agoWASHINGTON (AP) — Dr. Anthony Fauci, the top U.S. infectious disease expert until leaving the...
Fauci says the idea that he covered up a lab leak is ‘preposterous’ - The Boston Globe
The Boston Globe· 18 hours agoRepublicans on the panel have spent 15 months rooting through emails, Slack messages, and research...
China is trying to solve school bullying, but is it ready to face the causes?
South China Morning Post· 10 hours agoIn the eyes of some, the problem may have stemmed from familiar challenges in China. Psychiatrists...
The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for...
Morningstar· 4 hours agoThe Company has found that its lead nanoviricide broad-spectrum antiviral drug candidate NV-387, when given as a slow bolus intravenous infusion, resulted in a relatively flat plateau of blood ...
